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Available online 30 December 2015Itraconazole (ITZ) nanocrystal-containing powders were prepared through the combined use of high pressure
homogenization (HPH) and spray drying (SD). These powders were intended as base materials for the prepara-
tion of extemporary oral suspensions of the drug. The role and the effect of stabilizers on the size of re-dispersed
particles were studied using a mixture design and a Scheffé model relating the dried nanosuspension composi-
tion to the mean particle diameters. The homogenization process required a surface active agent (Tween 20)
to obtain the efficient comminution of itraconazole micronized powder. SD was carried out on ITZ
nanosuspensions after addition of a cellulose derivative (Methocel® E5) that allowed the prompt re-dispersion
of nanoparticles under “in use” conditions. The powders obtained by drying of homogenized systems showed
in vitro dissolution profile faster than that of the micronized drug, suggesting a potential ameliorated GI absorp-
tion of itraconazole released from the nanosuspensions.
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Among different strategies that can be used for enhancing the disso-
lution rate of poorly water-soluble drugs and leading to an ameliorated
bioavailability, particle size reduction to sub-micron range (typically
100–200 nm) seemed to be the simplest way to face the formulation
challenges (Mou et al., 2011; Möschwitzer, 2013; Gao et al., 2012;
Plakkot et al., 2011).
In the last ten years, many efforts have been spent in developing
pharmaceutical nanosuspensions and now some nanocrystal-based
products are available on the market (Rapamune®, Emend®, Tricor®
andMegace® ES) and others are currently being evaluated in clinical tri-
als (Baert et al., 2009; Hanafy et al., 2007; Shrewsbury et al., 2009;
Tuomela et al., 2014; Kumar and Burgess, 2012). Nanosuspensions are
biphasic systems constituted of nanocrystals, with dimensions ranging
between 10 and 1000 nm, dispersed in a liquid containing stabilizer
agents that lower the free surface energy of the nanoparticles and pre-
vent particle aggregation and/or particle growth.
Several processes can be used for the nanosuspension production;
they can be classified into “Bottom-up” such as nanoprecipitation or
nanocrystallization (Chan and Kwok, 2011; D'Addio and Prud'homme,
2011; Dandagi et al., 2011) and “Top-down” such as high pressureo).homogenization (Keck and Müller, 2006) and media milling
(Merisko-Liversidge et al., 2003; Merisko-Liversidge and Liversidge,
2011). Each of these technologies possesses advantages and disadvan-
tages; among the major drawbacks, the use of organic solvents and
the possible degradation of the active molecule can be cited.
Independently from the strategy adopted for the nanosuspension
production, the final product is invariably a system that suffers from
physical instability, linked to sedimentation, agglomeration/aggrega-
tion of particles and/or Ostwald's ripening phenomena. To avoid such
instability issues, the nanosuspension can be converted into a dry pow-
der. This solid material can be conveniently handled and used, either as
dosage form or as pre-formulate in the production of granules, tablets,
capsules or pellets (Cerea et al., 2015; Dolenc et al., 2009; Pinto and
Müller, 1999). Freeze drying (FD) and spray drying (SD) are techniques
of first choice to convert solutions and suspensions to powder and their
application to this purpose has been extensively investigated
(Abdelwahed et al., 2006; Lee, 2003; Vehring, 2008; Yin et al., 2005).
At time of use, the obtained dried nano-particulate systems should
be able to give aqueous dispersions characterized by particle size similar
to that of the original nanosuspension. To reach this goal, appropriate
stabilizers are added to the nanosuspension to lower the free surface
energy of the nanoparticles. The high surface free energy of nanoparti-
cles can be readily lowered by stabilizers that decrease the solid–
liquid interfacial tension (Rabinow, 2004), while particle aggregation
may be efficiently prevented or slowed down through adsorption of
Table 1
Preliminary experiments for component screening: low energy process of drug/stabilizer
aqueous dispersion.
System
Homogeneity
Cake aspect
After 15 min After 1 h After 24 h
ITZ-SLS +++ ++ + +
ITZ-TW20 ++++ ++++ + +
ITZ-TW60 ++ ++ + ++
ITZ-SP20 − − − +++
ITZ-SP60 − − − +++
ITZ-CRM +++ ++ + +++
ITZ-E50 − − − +
ITZ-E5 + − − +
ITZ-PLX +++ ++ + +
ITZ-CMC − + + +
ITZ-HEC − + + +
Homogeneity scale.−: absent; +: poor; ++: discrete; +++: good;++++: very good.
Cake scale.−: absent; +: loose; ++: solid; +++: very solid.
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2011). Surfactants (sodium dodecylsulphate, polysorbates, poloxamers),
polymers (cellulose derivatives, povidones) and sugars have been
employed, in many cases in mixture, to exploit their synergistic stabiliz-
ing effect (Van Eerdenbrugh et al., 2009).
The development of a dried nanosuspension containing itraconazole
was the objective of the present study: itraconazole, an antifungal drug
for the treatment of local and systemic mycoses, belongs to BCS class II,
having high permeability, but a very poor water solubility (less than
1 ngmL−1 at pH 7.0) (Peeters et al., 2002). The poor aqueous solubility
and high hydrophobicity limit its therapeutic efficiency and conse-
quently it has been object of many studies (Chaubal and Popescu,
2008; Cerdeira et al., 2013; Kumar et al., 2014; Segale et al., 2015) devot-
ed to develop pharmaceutical dosage forms with ameliorated biophar-
maceutical characteristics. The reduction of the particle size is one of
the strategies pursued for ITZ to improve its solubility and dissolution
rate with a view to increasing its bioavailability. Our interest was fo-
cused on a dried product containing a high amount of ITZ in form of
nanocrystals and able to promptly re-form a nanosuspension in contact
with water. Further aims were to model the ITZ particle diameter as a
function of system composition, and to investigate the role played by
the excipients on the comminution of ITZ particles and on the re-
dispersibility of dried suspension in water.
2. Materials and methods
2.1. Materials
Itraconazole (ITZ) was kindly donated by Chemo Group (E).
Hydroxypropylmethylcellulose Benecel® E50 (E50) was provided
by Ashland Inc. (KY, USA) and Methocel® E5 (E5) by Colorcon
(UK). Sodium carboxymethylcellulose (Blanose® 7 LF — CMC) and
hydroxyethylcellulose (Natrosol® 250 HX — HEC) were provided by
Hercules (USA). Polyethoxylated sorbitan esters (Tween 20 —
TW20 and Tween 60 — TW60), sorbitan monoesters (Span 20 —
SP20 and Span 80 — SP80) and sodium lauryl sulfate (SLS) were
purchased from Sigma-Aldrich (USA). Poly(ethylene oxide)/poly(pro-
pylene oxide) block copolymer (Pluronic® F127 — poloxamer, PLX)
and macrogolglycerol ricinoleate (Cremophor® ELP — CRM) were ob-
tained from BASF (D).
2.2. Evaluation of dispersion stability
A set of experimentswas performed for selecting the stabilizer or the
stabilizer mixture to be used for the production of the nano-powdered
formulation.
An amount of 0.125 g of each stabilizer (both surfactant and poly-
mer) was added to a water dispersion (10 mL) containing 1.25 g ITZ
and the system was treated by a disperser (UltraTurrax T25 IKA®,
D) at 24,000 rpm for 5min. The suspensionswere transferred in a grad-
uated cylinder and visually inspected for homogeneity after 15 min, 1 h
and 24 h using an arbitrary 4 points rating scale (see Table 1). An analog
arbitrary scale was used at time 24 h for evaluating the consistency of
the cake at the bottom of the cylinder (see Table 1).
2.3. High pressure homogenization
In exploratory tests, 3 different systems (100 mL) constituted of
water and ITZ alone, ITZ/Tween 20 (10/1 weight ratio) and ITZ/Tween
20/E5 (10/1/1weight ratio) respectivelywere processed by a high pres-
sure homogenizer (Microfluidizer M-110L, Microfluidics®, USA). The
coarse dispersions were pre-treated by a disperser (UltraTurrax T25
IKA®, 6500 rpm for 1 min) before applying the HPH process. In the
high energy process, pressure was set to 1000 bar, temperature at
25 °C and process time at 10min. After HPH treatment, the suspensionswere immediately analyzed for the particle size (Zave) and surface
charge (zeta potential, Zpot) by PCS.
In the body of the experimental work, HPH process was carried out
by the following procedure. ITZ coarse powder was dispersed by
UltraTurrax (6500 rpm for 1 min) in water containing an appropriate
amount of Tween 20. The suspension was transferred to the homoge-
nizer hopper and treated at constant temperature (25 °C) under
1200 bar for the different times (1 cycle lasted about 15 s). The
nanosuspension was recovered and immediately analyzed for particle
size determination.
Two sets of experiments were carried out: in the first, three suspen-
sions constituted of coarse ITZ in different amounts (corresponding to 3,
10 and 15% w/v) and TW20 in a fixed ratio with the drug (drug/
TW20 = 10/1 w/w) were submitted to HPH process. At pre-selected
time intervals (1, 2, 5, 10, 12, 20, 25, 40 and 60 min), samples (1 mL)
were withdrawn and immediately analyzed by PCS for particle size de-
termination. A second set of experiments (see 2.7. Mixture design) was
accomplished on systems composed of 10%w/v coarse ITZ and different
percentages of Tween 20 (ranging from 0.7 and 2.42% w/v): they were
homogenized for 25 min and, after withdrawal of 1 mL sample for PCS
analysis, the prescribed amount of E5 was added to the suspension,
which was dried as below described.
2.4. Spray drying
Nanosuspensions were dried by a Mini Spray Dryer B-290
(Buchi® Labortechnik, CH). The drying conditions were the same
for all the formulations (Cerea et al., 2015): inlet temperatures of
160 °C; air flux at 742 L/h, nozzle 0.6 mm diameter and a feeding
rate of 4 mL/min. Before drying, the equipment was equilibrated
using deionized water. The dried powders were recovered only
from the collection chamber.
2.5. Morphology and size of particles
The morphological properties of spray dried powders were investi-
gated using a scanning electron microscope (SEM; Sigma, Carl Zeiss,
D). Before scanning, the samples were coated with gold using a plasma
evaporator under vacuum. SEM images were acquired at an accelerated
voltage of 10 kV using different magnifications.
Particle size of micronized-ITZ wasmeasured on SEM pictures using
an image analysis software (Seneco, Motic Image Plus, Ver. 2.0 ML) an-
alyzing 20 particles on two different pictures for each sample.
The average size (Zave) and size distribution (Polydispersity
Index—PI) of nanoparticles were investigated by Photon Correlation
Spectroscopy (PCS) with a Zetasizer 3000HS (Malvern instrument,
UK) after HPH and after the spray drying process. Liquid formula-
tions were diluted with deionized water to obtain reproducible
Table 2
Setting of mixture design.
Exp. point⁎
Original coordinates “Pseudo” components
ITZ TW20 E5 ITZ TW20 E5
NS 1 0.660 0.060 0.280 0.000 0.000 1.000
NS 2 0.860 0.060 0.080 0.897 0.000 0.103
NS 3 0.860 0.083 0.057 0.897 0.103 0.000
NS 4 0.783 0.160 0.057 0.552 0.448 0.000
NS 5 0.660 0.160 0.180 0.000 0.448 0.552
NS 6 0.760 0.060 0.180 0.448 0.000 0.552
NS 7 0.822 0.122 0.057 0.724 0.276 0.000
NS 8 0.722 0.160 0.119 0.276 0.448 0.276
NS 9 0.660 0.110 0.230 0.000 0.224 0.776
NS 10 0.765 0.105 0.131 0.469 0.200 0.331
⁎ The middle point on the edge 2–3 has been deliberately omitted because it gave
no significant information.
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systems), like in the extemporary reconstitution of dispersed dosage
forms: an amount of powder corresponding to 0.20 g of ITZ was
dispersed in 25 mL water and manually shaken for 30 s. The re-
dispersed systems were further diluted with deionized water for
the PCS analysis. Two different samples of each formulation batch
were assessed: for each aliquot the results of three runs were collect-
ed and their average value was calculated. Zeta potential (Zpot) was
determined by Zetasizer 3000HS at 25.0 ± 1 °C. The re-dispersed
systems were diluted with 1 mM NaCl and the samples showed pH
values in the range 6.0–6.5. The Zeta potential values were calculated
using the Smoluchowski equation.
2.6. Differential scanning calorimetry
DSC analyses were performed with a Pyris 1 (Perkin Elmer, USA).
The samples were prepared introducing an aliquot of the sample equiv-
alent to 5 mg of ITZ in an aluminium pan that was then sealed. Thermal
scans were recorded at a heating rate of 5 °C min−1 under dry nitrogen
purge (20 mL min−1) from 25 to 200 °C.
2.7. Mixture design
The size of particles constituting the dried powders obtained byHPH
and SD combined processes was modelled as a function of the percent-
age composition of the systems. Amixture designwas used for planning
the systems to be tested: the proportions of ITZ, TW20 and E5 in the
dried product were considered as factors and the log 10 of the size
values of re-suspended powder particles represented the response
variable.
The experimental points were identified based on restrictions sug-
gested by the previous screening experiments: systems containing per-
centages of ITZ higher than 66.0% and lower than 86.0%, TW20 and E5 in
the range 6.0–16.0% and 6.0–28.0% respectively were considered. Based
on these constraints, a sub-region of the simplex (the complete domain
of ITZ/TW20/E5 mixture) was identified as the experimental domain
(Fig. 1). The mixture design was constructed selecting the most infor-
mative experimental points as dictated by Cornell (2002): they were
the extreme vertices of the polygonal experimental domain, themiddle
points of its edges and the centroid (Table 2).Fig. 1. Region of interest with experimental domain (grey zone) and experimental points o
surrounding the region of interest.Because of bounds placed on the factors, the region of interest is con-
fined to a limited region of the whole system domain and seemed nat-
ural to redefine its coordinates in term of “pseudo” components
(combination of the original component coordinates). This transforma-
tion made the comprehension of the design and the fitting of models
easier and increased the precision of coefficient estimates. In Table 2,
the design setting in the original variables and in “pseudo” components
of dried suspensions is reported; the same was also illustrated in Fig. 2.
Such a design allowed to calculate up to a complete third degree model
and provided information for detecting the curvature of the response
surface and for validating the model itself.
A special cubic Scheffé model was fitted to the logarithm of experi-
mental data in “pseudo” coordinates (denoted with a prime):
logZave ¼ b1ITZ
0 þ b2TW20
0 þ b3E5
0 þ b12ITZ
0
∙TW20
0 þ b13ITZ
0
∙E5
0
þ b23TW20
0
∙E5
0 þ b123ITZ
0
∙TW20
0
∙E5
0
:
Multivariate regression analysis was performed by a cross-validated
procedure implemented via R-software (version 3.1.0).
The total effect of each system component was evaluated as pro-
posed by Piepel (Cornell, 2002; Piepel, 1982). In brief, the centroid of
our experimental domain was taken as reference mixture and the linef mixture design: in detail the whole simplex of ITZ-TW20-HPMC mixture with a box
Fig. 2. Experimental domain of mixture design: components are re-defined in “pseudo”
components; dashed lines represent the “Piepel's directions” of each component.
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was defined as “Piepel's direction” (Fig. 2). This is the direction along
which the proportion of component i increases (or decreases), those
of remaining 2 components decrease (or increase), but the ratio
among the remaining components stay the same. Coordinates of mix-
tures along the Piepel's direction of component i were calculated and
substituted into the fitted model to obtain their predicted response
values. Plotting them against incremental values of the selected compo-
nent (within the experimental region) gave the curves showing the ef-
fect of each component.
2.8. Dissolution tests
The dissolution tests were carried out on some of the dried
nanosuspensions and on a physical mixture (PM 5) constituted of
coarse ITZ (66.0%), TW20 (16.0%) and E5 (18.0%). A dissolution ap-
proach published in the literature for nanoparticulate formulations
(Chaubal and Popescu, 2008; Crisp et al., 2007) was applied. Dissolution
testing was conducted by first adding the dried nano-powder or the
physical mixture to water and mixing for up to 5 min at 37 °C to allow
thorough wetting of the particles; then the suspension was transferred
to the dissolution medium.
An USP dissolution apparatus 2 (AT7 Smart, Sotax, CH; 100 rpm,
37.0 ± 0.5 °C, n= 6) was employed. The dissolution mediumwas Sim-
ulated Gastric Fluid without enzymes (SGF) (USP 36) (900mL); the use
of surfactants in the dissolutionmediumwas avoided to primarily assay
the effects of the dimensional characteristics of particles on the dissolu-
tion process. An amount of material corresponding to 4 mg of ITZ (ITZ
solubility in SGF is 5.0 μgmL−1)was introduced into the vessel. Samples
were withdrawn at fixed time points, filtered and spectrophotometri-
cally assayed for the drug content (UV 220 nm, Lambda 35, Perkin
Elmer, I).
For comparing the drug release profiles, the similarity factor f2 was
used considering that f2 values greater than 50 (50–100) assess similar-
ity or equivalence of the two curves (FDA, 1997).
3. Results and discussion
3.1. Preliminary studies
The first set of preliminary experimentswas carried out by a low en-
ergy homogenization process with the aim of selecting suitable excipi-
ents for an efficient homogenization of suspensions. Among the
various surfactants and polymers, Tween 20 seemed to be the mostperforming one, since it gave a suspension, which remained homoge-
neous for at least 1 h (Table 1).
All of the polymers, with the exception of the poloxamer (PLX), led
to suspensions less stable and homogeneous than those obtained with
the surfactants, but they gave a loose settling of the suspension, reduc-
ing the risk of an irreversible agglomeration of drug particles.
Since in our case, the nanosuspensions were intended to be spray
dried immediately after the size reduction treatment, the long-term sta-
bility of the systems was not investigated. These results suggested the
selection of Tween 20 and of a cellulose derivative as components of
the formulation under development. Among polymers, our choice was
E5 because this compound has a lower MW than E50. As a result,
when it comes in contact with water it exhibits a faster dissolution
and gives a colloidal solution characterized by a lower viscosity (Dow,
2002). These characteristics could be particularly important for the pro-
duction of a powder that should re-disperse promptly in water at time
of dispensing giving rise to an extemporary suspension.
The preliminary HPH experiments, carried out on aqueous disper-
sions containing pure drug, drug/TW20 or ITZ/TW20/E5, showed that
the surfactant is essential for an efficient comminution of the drug. In
fact, after HPH, the particle size of pure ITZ suspension was significantly
higher than that of ITZ/TW20 system (Zave N 2000 nm and 677.4 ±
53.1 nm respectively). It has also been observed that the polymer does
not have a relevant effect on the extent of size reduction of particles:
the particle size for ITZ/TW20/E5 system accounted for 714.3 ±
42.8 nm, not significantly different from that of ITZ/TW20 suspension
(p N 0.01). The comparison of measured Zpot values for these systems
indicated that neither the surfactant, nor the cellulose derivative
modified remarkably the surface charge characteristics of particles:
Zpot =−32mV for pure ITZ system; Zpot =−30mV for ITZ/TW20 sys-
tem and Zpot = −27 mV for ITZ/TW20/E5 system. Since E5 did not
meaningfully modify the performances and the outcome of HPH pro-
cess, the cellulose polymer was added to the nanosuspension subse-
quently to the homogenization treatment and just before the spray
drying process.
In the HPH experiments, it was also observed that suspensions
containing the drug in concentration higher than 25% (w/v) led to
the clogging of the homogenizer and did not allow the profitable ho-
mogenization treatment of dispersions.
3.2. Homogenization and spray drying of nanosuspensions
The degree of comminution obtainable by HPH is related to the op-
erative conditions applied in the process and, most of all, to the homog-
enization time and pressure and to the processing temperature
(Pardeike and Müller, 2010). In the present work, the homogenization
pressure was set at 1200 bar, so that the energy applied per time unit
was equal for all the formulations: the temperature was maintained at
25 °C throughout the process. Systems constituted of ITZ and Tween
20 at constant weight ratio 10:1, differing for the percentage of solid
dispersed in water (3, 10 and 15%), were submitted to transit into the
homogenizer chamber for different times (cycles). Size and size distri-
bution of particles after selected processing times were measured.
Starting from a ITZ powder constituted of particles 8.9 μm in mean
diameter, suspensions with particles in the nanometric range were ob-
tained. Increasing the number of homogenization cycles, the particle
size diminished and simultaneously a continuous narrowing of the
width of the particle size distribution was observed (Fig. 3a–b).
The profile of size reduction of three ITZ suspensions (Fig. 3a)
followed a trend similar to that observed by other researchers
(Pardeike andMüller, 2010). Themost conspicuous decrease was with-
in about 20min (about 75 cycles) and after this time the change in par-
ticle size was less evident: as previously reported by Plakkot et al.
(2011), the comminution in the latter stages of process occurred by
abrasion rather than fragmentation of particles. The Zave curve for the
10% ITZ system almost overlapped that of the 3% drug suspension,
Fig. 3. Size reduction of ITZ particles by HPH process: particle size (Zave) (a) and Polydispersity Index (PI) (b) as a function of time and number of HPH cycles. ITZ/TW20 weight ratio was
kept constant (10/1).
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values, suggesting that the high concentration of particles reduced the
efficacy of their collisions during the treatment. Even though the num-
ber of the investigated systems was limited, it can be asserted that
amounts of solid ≤10% did not affect the particle size reduction of the
product. Increasing the number of homogenization cycles, the polydis-
persity index (PI) diminished (Fig. 3b), providing nanonized powders
with a higher degree of homogeneity and thus less prone to the poten-
tial effects of Ostwald's ripening. The diminution of PI (increase of
homogeneity) on increasing times (cycles) was particularly evident
for the 15% ITZ suspension.
These findings oriented the choices for the HPH treatments in the
successive mixture design: the processing conditions were fixed at
1200bar for 25min (90 homogenization cycles) at 25 °C employing sus-
pensions containing 10% ITZ in order to obtain products constituted of
particles of nanometric dimensions and stable enough for the drying
process.
Liquid vehicle removal was carried out by spray drying with the aim
of obtaining powders that, when re-dispersed in water, were able to
form again suspensions containing particles of original nanometric
size. A further desired feature of the powders is their complete de-
agglomeration in water when shaken for few seconds, i.e. in conditions
miming those used by a patient at the administration of the medicinal.The presence of the employed cellulose derivative E5 would delay the
crystal growth by reducing particle interactions and consequently
would diminish the potential for agglomeration (Plakkot et al., 2011).
The hydrophilic polymer E5was added to ITZ/TW20 suspensions before
spray drying. Drying conditions used for all nanosuspensions were the
same to avoid any influence of the process on the aggregation of
nanocrystals, as experienced by other authors (Chaubal and Popescu,
2008).
3.3. Mixture design study
The influence of the cellulose derivative and the possible effects of
the surfactant on the size of re-dispersed ITZ powderswere investigated
and a regression model describing the relationship among the size of
particles and the amount of powder components was searched. The
study was accomplished by a mixture design approach (Table 2),
which involved the preparation of ten suspensions constituted of differ-
ent proportions of ITZ, TW20 and E5. ITZ and TW20, in the proportions
of design, were dispersed in water, homogenized and analyzed for par-
ticle size determination: for all nanosuspensions (NS) (Table 3), mean
particle diameters were lower than 500 nm and PI values accounted
for a discrete size distribution homogeneity (b0.52). After the addition
of E5, the suspensions were spray dried.
Table 3
Dimensional characteristics of nanosuspensions (NS) and re-dispersed dried
nanopowders (r-NS): S.D. values in brackets, the values are means of three samples.
Exp. point
After HPH (NS) After redispersion (r-NS)
Zave (nm) P.I. Zave (nm) P.I.
1 313.0 (4.6) 0.38 (0.05) 424.8 (14.2) 0.32 (0.09)
2 338.6 (1.4) 0.41 (0.05) 703.7 (38.6) 1.00 (0.00)
3 371.6 (12.1) 0.52 (0.05) 1169.8 (105.3) 1.00 (0.00)
4 441.0 (13.1) 0.45 (0.03) 712.8 (58.5) 0.98 (0.04)
5 439.5 (32.5) 0.37 (0.04) 492.5 (35.1) 0.62 (0.12)
6 443.0 (12.7) 0.30 (0.03) 399.1 (15.5) 0.44 (0.08)
7 455.9 (9.6) 0.40 (0.08) 1187.7 (49.4) 1.00 (0.00)
8 379.9 (9.1) 0.36 (0.04) 440.3 (14.5) 0.42 (0.11)
9 371.4 (13.5) 0.36 (0.03) 432.6 (20.5) 0.34 (0.05)
10 368.1 (11.6) 0.33 (0.05) 440.7 (7.2) 0.45 (0.08)
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possible modification of the physical status of the drug. DSC traces for
the pure drug, a physical mixture of the three components and the cor-
respondingNS 5 powder are reported in Fig. 4. For the physical mixture,
a thermal profile very different from that of the pure drug was ob-
served: as expected, the presence of E5 and Tween 20 determined the
shift of the onset and peak temperatures of the drug. The comparison
between formulation NS 5 and the physical mixture revealed a thermal
behaviour very similar, that suggests a practically identical structure for
the two types of systems and the assignment of the peak around 160 °C
to the melting of ITZ nanocrystals. The slight reduction of DSC parame-
ters for the formulation NS 5 can be attributed to themore efficient heat
transfer during the DSC analysis for the nanonized-ITZ-containing pow-
der in comparison to that for physical mixture PM 5 that contains ITZ
particles of higher dimension.
The powders were alsomicroscopically observed and the inspection
gave evidence of their structure. From the SEM pictures of NS 5 powder
(Fig. 5), it can be appreciated that SD powders were agglomerates of
variable dimensions, constituted of big, spherical and collapsed particles
(whose diameter ranged from 5 to 25 μm)with adhered and embedded
small particles (b2 μm in diameter) on their surface. We suppose that
the largest units were E5 particles formed during the drying process,
while the smallest ones nanocrystals of ITZ covered/agglomerated by
the excipients.
The powders re-dispersed quickly in water by shaking (250 mg in
25 mL of water, r-NS systems) and gave suspensions that did notFig. 4. DSC profile of E5, ITZ-TW20-E5 physical mixtureshow sedimentation for 5 h. Cellulose derivative E5 units, when in con-
tactwithwater, re-hydrated and dissolved in few seconds leading to the
complete separation of agglomerates present in the powder. PCS analy-
sis (Table 3) showed increased particle size values for most of r-NS sys-
tems due to the adhesion of E5 on the surface of ITZ nanocrystals. For
powders containing low percentages of E5 (r-NS 3 and r-NS 7), the
size valueswere particularly higher than those before drying: this result
indicated strong interactions among nanocrystals during SD process,
that led to their stable aggregation. This finding could probably be due
to the low proportion of E5 in the system.
In the study of the relationship among the particle dimension and
the components of mixtures, we used the logarithm of Zave instead of
Zave values: this transformation obtained a set of data for which the dis-
tribution of the error terms is close to a normal distribution. Logarithmic
particle size values of the different batches of powderswere fitted to the
Scheffé special cubic model and a cross-validated regression algorithm
was applied to the data of Table 4. The method gave a model whose co-
efficient estimates and statistical parameters are reported in Table 5.
This model adequately described the correlation between the particle
size and the proportion of components, as proved by resulting statistical
parameters.
The contour plot depicted in Fig. 6 illustrates the complexity of the re-
lationship between response and formulation variables. An estimate of
the effects of mixture components was calculated substituting the
“pseudo” coordinates of blends along each “Piepel's direction” into the
fittedmodel. A set of predicted response valueswere obtained and the re-
sponse trace constructed. The plot of Fig. 7 graphically illustrates the
effects of each mixture component in “pseudo” coordinates.
A significant effect of ITZ on the log mean diameter of particles can
be appreciated, log Zave diminishing for systems constituted by propor-
tions ≤0.713 of ITZ (0.239 in “pseudo” coordinates) and increasing for
higher proportions of the drug. A more remarkable effect is shown by
E5, the log mean diameter of particles diminishing for increasing pro-
portions of the stabilizing agent, with a minimum value for the suspen-
sion containing a proportion of 0.210 E5 (0.671 in “pseudo”
coordinates) and low increment for higher content of this component.
Tween 20 has limited effect on the particle size, as testified by the low
variation of response over all TW20 proportion range along the direc-
tion this component effect is measured. These results indicate that E5
plays a very important role in determining the size of particles of re-
dispersed powder; a proportion of the stabilizer around 21% represents
the optimal level for powders that will give suspensions with particlesPM 5, NS 5 powder and micronized-ITZ powder.
Fig. 5. SEM pictures of NS 5 system at two different magnifications.
181A. Foglio Bonda et al. / European Journal of Pharmaceutical Sciences 83 (2016) 175–183of minimum size. Moreover, the surfactant seems to have a very limited
effect on the re-suspended particle size, but, as above reported, it is es-
sential for the comminution of ITZ during HPH.
The good predictive ability of the calculated model is demonstrated
by the high value of RCV2 (=0.9073). To reinforce this, the model was
used to predict theparticle size value of amixture inside the experimen-
tal space that could represent a valuable formulation for the extempo-
rary ITZ suspension. The mixture used as validation point was selected
taking into account the effects of polymeric stabilizing agent and drug
on the particle size: the proportion of surfactant was calculated as com-
plement of the system. The validation mixture, constituted of 68.7% ITZ,
13.3% Tween 20 and 18.0% E5 (corresponding to 0.448, 0.179 and 0.373Table 4
Matrix of data for model calculation.
r-NS exp. point N. of batches
“Pseudo”
components Zave (nm)⁎ Log Zave P.I.
ITZ TW20 E5
1 3 0.000 0.000 1.000
412.8 2.616 0.29
439.0 2.642 0.30
422.7 2.626 0.36
2 3 0.897 0.000 0.103
731.1 2.864 1.00
658.9 2.819 1.00
721.3 2.858 1.00
3 3 0.897 0.103 0.000
1105.3 3.028 1.00
1248.1 3.096 1.00
1091.5 3.037 1.00
4 3 0.552 0.448 0.000
728.3 2.862 1.00
675.2 2.829 0.96
735.0 2.865 1.00
5 5 0.000 0.448 0.552
447.8 2.651 0.46
547.8 2.738 0.63
509.2 2.707 0.72
505.5 2.704 0.65
492.0 2.691 0.69
6 3 0.448 0.000 0.552
385.4 2.586 0.39
409.2 2.612 0.56
402.7 2.605 0.38
7 5 0.724 0.276 0.000
1213.3 3.084 1.00
1990.0 3.299 1.00
1206.9 3.081 1.00
1143.1 3.058 1.00
1404.0 3.147 1.00
8 3 0.276 0.448 0.276
445.4 2.649 0.37
448.0 2.651 0.46
427.6 2.631 0.43
9 3 0.000 0.224 0.776
454.2 2.657 0.32
433.8 2.637 0.34
409.7 2.612 0.37
10 7 0.469 0.200 0.331
432.4 2.636 0.44
443.7 2.647 0.47
437.5 2.641 0.48
449.1 2.652 0.42
528.5 2.723 0.90
476.5 2.678 0.53
432.5 2.636 0.52
⁎ Each value is the mean of two replicates.in “pseudo” coordinates, respectively), was homogenized and dried, as
previously described, and diameter and size distribution of particles
were determined by PCS after re-suspension of the powder in water.
The experimental size value (434.1 ± 25.5 nm) of this system was
very close to the predicted one (415.0 nm), confirming the high reliabil-
ity of the model for the prediction of the particle size of our ITZ blends.
Dissolution behaviour of dried nanoparticles was tested in SGF for
simulating the gastric environment. As an example, in Fig. 8, the disso-
lution profile of re-dispersed ITZ powder r-NS 5 is reported and com-
pared with the corresponding physical mixture prepared with the
micronized drug (PM 5). Differently from other authors (Chaubal and
Popescu, 2008), the release profiles did not reveal an initial lag time
which could have been referred to a disintegration step of aggregates:
the pre-dispersion treatment of powders and the good disaggregating
properties of E5 accounts for this finding. As expected, the dissolution
of nanonized ITZ powderwasmarkedlymore rapid than that of physical
mixture PM 5, being the surface area of drug particles substantially in-
creased by HPH process. For the nanonized formulation, after 15 min
the solubilized ITZ accounts for 83.0%, while, for themicronized ITZ sys-
tem PM 5, the percentage of drug in the medium was only 46.0%. Less
than 1 h is required for the complete dissolution of the drug from the
system containing nanoparticles (492.5 nm in diameter), allowing to
expect an increased bioavailability of itraconazole when administered
in vivo.4. Conclusions
High pressure homogenization and spray drying combination
allowed the production of ITZ-containing powders that can be used as
a base of extemporaneous suspensions. These powders contained high
proportions of drug in form of agglomerates of nanocrystals coated
and/or embedded by a mixture of excipients. The agglomerates easily
re-disperse upon contact with water in conditions simulating those of
actual use in administrating suspensions. The increased drug dissolu-
tion rate allows expecting an enhanced bioavailability of ITZ when
administered in form of nanosuspension. Based on these findings, it
has been hypothesized that the nanonized-ITZ powders could be
employed as intermediate for the production of other oral drug dosage
forms and further works are in progress in order to demonstrate this
hypothesis.Table 5
Coefficient estimates of the Scheffé special cubic model and related statistical parameters.
Coefficient Estimate St. Error t value p
b1 3.119 0.035 88.378 b2.00 ∙ 10−16
b2 2.712 0.064 42.341 b2.00 ∙ 10−16
b3 2.640 0.038 70.401 b2.00 ∙ 10−16
b13 −1.331 0.177 −7.506 1.03 ∙ 10−08
R2= 0.9992; Adjusted R2= 0.9992; Res. St. Error= 0.0809 (34 df); F4,34 = 1.12 ∙ 104;
p b 2.20 · 10−16; RCV2 = 0.9073.
Fig. 6. Contour plot of log particle size as a function of component proportions in nano-
powders.
Fig. 8. Dissolution profiles of nanonized ITZ powder (r-NS 5) and of corresponding
physical mixture (PM 5).
182 A. Foglio Bonda et al. / European Journal of Pharmaceutical Sciences 83 (2016) 175–183The mathematical model adequately describes the relationship be-
tween the size of particles and the composition of suspensions and clar-
ifies the role played by the employed stabilizingmixture. The surfactant
seems primarily involved as wetting agent in the comminution process
and the cellulose polymer as de-agglomerating/separating agent of
spray-dried formulation. The resulting model can be used as a valuable
tool for obtaining systemswith the desired dimensional characteristics.
List of main abbreviationsCMC Blanose® 7 LF (sodium carboxymethylcellulose)
CRM Cremophor® ELP (polyoxyl 35 hydrogenated castor oil)
E5 Methocel® E5 (hydroxypropylmethylcellulose; 5 mPa·s)
E50 Benecel® E50 (hydroxypropylmethylcellulose; 50 mPa·s)
F F test value
FD freeze drying
HEC Natrosol® 250 HX (hydroxyethylcellulose)
HPH high pressure homogenization
ITZ itraconazole
NS nanosuspension
PCS Photon Correlation Spectroscopy
PI polydispersity index
PLX Pluronic® F127 (poly(ethylene oxide)/poly(propylene oxide)
block copolymer)Fig. 7. Effect of formulation components on the particle size of re-dispersed dried
nanosuspensions (r-NS).PM physical mixture
r-NS reconstituted nanosuspension
RCV
2 cross-validated correlation coefficient
SD spray drying
SGF simulated gastric fluid
SLS sodium lauryl sulphate
SP20 Span 20 (sorbitane monolaurate)
SP60 Span 60 (sorbitane monostearate)
TW20 Tween 20 (polyoxyethylene (20) sorbitan monolaurate)
TW60 Tween 60 (polyoxyethylene (20) sorbitan monostearate)
Zave average size of particles
Zpot zeta potential
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